Shots:

• The P-III (HIMALAYA) trial evaluates Imfinzi (1500mg, q4w) + tremelimumab (300mg) vs sorafenib in 1324 patients with HCC prior not treated with systemic therapy & not eligible for LRT at 190 centers across 16 countries
• The results showed an improvement in OS, 22% reduction in risk of death, m-OS (16.4mos. vs 13.8mos.), patients were alive @3yrs. (31% vs 20%), improvement in ORR (20.1% vs 5.1%), m-DoR (22.3mos. vs 18.4mos.), no bleeding risk, safety profiles were consistent with a known profile of product & no new safety signals
• Treatment discontinuation due to AEs (8.2% & 4.1% vs 11%). Imfinzi is being studied as monothx. & combination with other anti-cancer treatments for solid tumors

Ref: AstraZeneca | Image: Mint